- Global Pharma News & Resources

Adrenocortical Carcinoma Treatment Market Top Manufacturers, Demand Analysis, Global Industry Size, Competitive Share, Future Technologies and Trends Overview 2018 – 2026

SEATTLE, March 25, 2021, (PHARMIWEB) — Adrenocortical carcinoma is a rare cancer affecting the outer layer of the adrenal glands, which are responsible for producing certain hormones and maintaining optimum blood pressure levels. Adrenocortical carcinoma is relatively frequent in children compared to other cancers, although the cancer may also affect adults. The most common symptoms of adrenocortical carcinoma include abdominal pain, hypertension, weight gain, and frequent urination, which is mainly caused due to tumors causing excess secretion of hormones from the adrenal glands. Mitotane is the only drug approved by the U.S. Food and Drug Administration (FDA) and European Medicine Executive Agency (EMEA) for treatment of metastatic adrenocortical carcinoma. Diagnosis of adrenocortical carcinoma is based on urine tests, dexamethasone suppression test for detecting abnormal levels of cortisol, which is the hormone released by the adrenal glands. Also, a wide number of imaging devices are used for diagnoses of the disease, which include CT scan, MRI, PET scan, and MIBG Scan, thus facilitating faster disease identification that helps doctors to decide further treatments.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@

Adrenocortical Carcinoma Treatment Market: Market Dynamics

Increasing incidence of adrenocortical carcinoma associated with genetic disorders is a major factor augmenting growth of the adrenocortical carcinoma treatment market. According to the Journal of Clinical Endocrinology & Metabolism, 2013, the peak incidence of adrenocortical carcinoma ranges between 40-50 years, where women are 55–60% more likely to get affected with a ratio of 1.5:1. The study also states that adrenocortical carcinoma is a rare and highly aggressive malignancy with an annual incidence of 0.05–0.2% or 1-2 cases per million population globally. Also, inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with increasing incidence of adrenocortical carcinoma. According to a survey by Endocrine Society, 2014, adrenocortical carcinoma accounts for around 3-10% of the malignancies in LFS and over 5-15% malignancies in BWS. Moreover, according to the study published by Medscape in 2017, adrenocortical carcinoma accounted for 0.02-0.2% of all cancer-related deaths, globally.

Moreover, the number of clinical trials for different chemotherapeutics is increasing. For instance, Millendo Therapeutics, Inc. initiated Phase 1 trial for ATR-101 in 2013 to treat adrenocortical carcinoma. Also, the National Cancer Institute initiated a Phase II trial of Cisplatin and sodium thiosulfate for surgical resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for adrenocortical carcinoma. Also, in March 2018, the University of Colorado Anschutz Medical Campus presented new models to identify genetic targets and tests, and promising treatments for adrenocortical carcinoma at the ENDO Conference, thus exploring new therapeutic options for the patients.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Adrenocortical Carcinoma Treatment Market Research Report:

Adrenocortical Carcinoma Treatment Market: Regional Dynamics

Regional segmentation of the global adrenocortical carcinoma treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global adrenocortical carcinoma treatment market over the forecast period owing to rising prevalence of the disease and presence of key players who are focusing on developing novel products. According to the National Institutes of Health Office of Rare Diseases Research, the incidence rate of adrenal cancer is about 600 new cases per year in the U.S. Moreover, institutions such as the University of Michigan Rogel Cancer Center are involved in stem cell research, to advance the treatment of adrenal cancer.

The Latin America market is expected to gain significant traction over the forecast period owing to higher incidence of the condition in Brazil. According to a survey by the ACC C.U.R.E. Organization, adrenal cancer in Brazil is 15 times more prevalent than any other countries in the world, due to high prevalence of mutations of a single gene called TP53. Also, according to the Endocrine Society, in 2014, childhood incidence is 2.9 to 4.2 million per year in Brazil compared to an estimated annual incidence of 0.2 to 0.3 million children worldwide. Moreover, the University of Michigan has been collaborating with the Adrenal Cancer Group in Sao Paulo to bring about advancements in adrenal cancer research, in order to provide better clinical outcomes for patients in the region.

Adrenocortical Carcinoma Treatment Market: Competitive Analysis

Manufacturers are focused on launching novel therapeutic products for treatment of rare diseases which is accelerating the market growth. For instance, in 2017, the FDA approved immunotherapy drug Keytruda (Pembrolizumab), which is the first anti-PD-1 (programmed death receptor-1) therapy developed by Merck & Co. and indicated for advanced adrenocortical carcinoma.

Key players operating in the global adrenocortical carcinoma treatment market include ArQule, Inc., EnGeneIC Ltd., Exelixis, Inc., Merck & Co., Millendo Therapeutics, and Orphagen Pharmaceuticals, Inc.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @

Adrenocortical Carcinoma Treatment Market: Market Taxonomy

On the basis of therapy type, the global adrenocortical carcinoma treatment market is segmented into:

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Adjuvant Therapy

On the basis of disease type, the global adrenocortical carcinoma treatment market is segmented into:

  • Localized adrenocortical carcinoma
  • Metastatic adrenocortical carcinoma

On the basis of end user, the global adrenocortical carcinoma treatment market is segmented into:

  • Hospital
  • Clinics
  • Ambulatory Surgical Centers

On the basis of end user, the global adrenocortical carcinoma treatment market is segmented into:

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa

Table of Content

Global Adrenocortical Carcinoma Treatment Market Research Report
Section 1: Global Adrenocortical Carcinoma Treatment Industry Overview
Section 2: Global Economic Impact on Adrenocortical Carcinoma Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Adrenocortical Carcinoma Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Adrenocortical Carcinoma Treatment Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 25-Mar-2021